Oncol Case Rep J | Volume 3, Issue 2 | Case Report | Open Access
Rabia Z Mayer1*, George Ansstas2 and Milan J Anadkat1
1Division of Dermatology, Washington University School of Medicine, USA
2Division of Oncology, Washington University School of Medicine, USA
*Correspondance to: Milan J. Anadkat
Fulltext PDFThe prognosis for advanced and metastatic malignancies has been significantly altered due to the use of check point inhibitors. Due to the activation of CD4+/CD8+ cytotoxic T-cells, these drugs have a unique spectrum of adverse effects, of which cutaneous manifestations are the most common.
This case report describes the first instance of pembrolizumab-induced neutrophilic dermatosis of the dorsal hands, a rare and localized variant of Sweet’s syndrome in a patient being treated for metastatic melanoma.
Mayer RZ, Ansstas G, Anadkat MJ. Pembrolizumab-Induced Neutrophilic Dermatosis of the Dorsal Hands. Oncol Case Report J. 2020;3(2):1024..